Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 62

1.

Characterisation of the cell line HC-AFW1 derived from a pediatric hepatocellular carcinoma.

Armeanu-Ebinger S, Wenz J, Seitz G, Leuschner I, Handgretinger R, Mau-Holzmann UA, Bonin M, Sipos B, Fuchs J, Warmann SW.

PLoS One. 2012;7(5):e38223. doi: 10.1371/journal.pone.0038223. Epub 2012 May 30.

2.

Anti-tumor activity of sorafenib in a model of a pediatric hepatocellular carcinoma.

Nagel C, Armeanu-Ebinger S, Dewerth A, Warmann SW, Fuchs J.

Exp Cell Res. 2015 Feb 1;331(1):97-104. doi: 10.1016/j.yexcr.2014.10.018. Epub 2014 Oct 31.

PMID:
25447203
3.

Molecular cytogenetic evaluation of virus-associated and non-viral hepatocellular carcinoma: analysis of 26 carcinomas and 12 concurrent dysplasias.

Zondervan PE, Wink J, Alers JC, IJzermans JN, Schalm SW, de Man RA, van Dekken H.

J Pathol. 2000 Oct;192(2):207-15.

PMID:
11004697
4.

Glutamine depletion by crisantaspase hinders the growth of human hepatocellular carcinoma xenografts.

Chiu M, Tardito S, Pillozzi S, Arcangeli A, Armento A, Uggeri J, Missale G, Bianchi MG, Barilli A, Dall'Asta V, Campanini N, Silini EM, Fuchs J, Armeanu-Ebinger S, Bussolati O.

Br J Cancer. 2014 Sep 9;111(6):1159-67. doi: 10.1038/bjc.2014.425. Epub 2014 Jul 29.

5.
6.

C1orf61 acts as a tumor activator in human hepatocellular carcinoma and is associated with tumorigenesis and metastasis.

Hu HM, Chen Y, Liu L, Zhang CG, Wang W, Gong K, Huang Z, Guo MX, Li WX, Li W.

FASEB J. 2013 Jan;27(1):163-73. doi: 10.1096/fj.12-216622. Epub 2012 Sep 25.

PMID:
23012322
7.

Combined functional genome survey of therapeutic targets for hepatocellular carcinoma.

Satow R, Shitashige M, Kanai Y, Takeshita F, Ojima H, Jigami T, Honda K, Kosuge T, Ochiya T, Hirohashi S, Yamada T.

Clin Cancer Res. 2010 May 1;16(9):2518-28. doi: 10.1158/1078-0432.CCR-09-2214. Epub 2010 Apr 13.

8.
9.

Identification of LZAP as a new candidate tumor suppressor in hepatocellular carcinoma.

Zhao JJ, Pan K, Li JJ, Chen YB, Chen JG, Lv L, Wang DD, Pan QZ, Chen MS, Xia JC.

PLoS One. 2011;6(10):e26608. doi: 10.1371/journal.pone.0026608. Epub 2011 Oct 19.

10.

Molecular background of alpha-fetoprotein in liver cancer cells as revealed by global RNA expression analysis.

Saito S, Ojima H, Ichikawa H, Hirohashi S, Kondo T.

Cancer Sci. 2008 Dec;99(12):2402-9. doi: 10.1111/j.1349-7006.2008.00973.x. Epub 2008 Nov 24.

11.

RASSF1A expression inhibits the growth of hepatocellular carcinoma from Qidong County.

Xue WJ, Li C, Zhou XJ, Guan HG, Qin L, Li P, Wang ZW, Qian HX.

J Gastroenterol Hepatol. 2008 Sep;23(9):1448-58. Epub 2007 Aug 6.

PMID:
17683489
12.

ESM-1 silencing decreased cell survival, migration, and invasion and modulated cell cycle progression in hepatocellular carcinoma.

Kang YH, Ji NY, Lee CI, Lee HG, Kim JW, Yeom YI, Kim DG, Yoon SK, Kim JW, Park PJ, Song EY.

Amino Acids. 2011 Mar;40(3):1003-13. doi: 10.1007/s00726-010-0729-6. Epub 2010 Sep 7.

PMID:
20821239
13.

[Establishment of the human hepatocellular carcinoma cell line and its characteristics].

Sasaki F, Kameda H, Hata Y, Uchino J.

Hum Cell. 1988 Mar;1(1):89-91. Japanese.

PMID:
2856442
14.
15.

Ephrin-A1 expression contributes to the malignant characteristics of {alpha}-fetoprotein producing hepatocellular carcinoma.

Iida H, Honda M, Kawai HF, Yamashita T, Shirota Y, Wang BC, Miao H, Kaneko S.

Gut. 2005 Jun;54(6):843-51.

16.

ShRNA-targeted centromere protein A inhibits hepatocellular carcinoma growth.

Li Y, Zhu Z, Zhang S, Yu D, Yu H, Liu L, Cao X, Wang L, Gao H, Zhu M.

PLoS One. 2011 Mar 15;6(3):e17794. doi: 10.1371/journal.pone.0017794.

17.

Mybl2 expression is under genetic control and contributes to determine a hepatocellular carcinoma susceptible phenotype.

Frau M, Ladu S, Calvisi DF, Simile MM, Bonelli P, Daino L, Tomasi ML, Seddaiu MA, Feo F, Pascale RM.

J Hepatol. 2011 Jul;55(1):111-9. doi: 10.1016/j.jhep.2010.10.031. Epub 2010 Dec 7.

PMID:
21419759
18.

A new human pleomorphic hepatocellular carcinoma cell line, KYN-2.

Yano H, Maruiwa M, Murakami T, Fukuda K, Ito Y, Sugihara S, Kojiro M.

Acta Pathol Jpn. 1988 Aug;38(8):953-66.

PMID:
2847482
19.
20.

The activation of MEK/ERK signaling pathway by bone morphogenetic protein 4 to increase hepatocellular carcinoma cell proliferation and migration.

Chiu CY, Kuo KK, Kuo TL, Lee KT, Cheng KH.

Mol Cancer Res. 2012 Mar;10(3):415-27. doi: 10.1158/1541-7786.MCR-11-0293. Epub 2012 Jan 12.

Supplemental Content

Support Center